^
    Back
    Association details:
    Biomarker:PIK3CA E542K
    Cancer:Breast Cancer
    Drug:Opsiria (sirolimus) (mTOR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Proc Natl Acad Sci U S A
    Title:

    Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

    Excerpt:
    We have determined the growth-regulatory and signaling properties of the three most frequently observed PI3-kinase mutations: E542K, E545K, and H1047R….The inhibitor of TOR, rapamycin, strongly interferes with cellular transformation induced by the PI3-kinase mutants, suggesting that the TOR and its downstream targets are essential components of the transformation process.
    DOI:
    10.1073/pnas.0408864102